Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析

◆英語タイトル:Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH57970FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Hikma Pharmaceuticals Plc (HIK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Feb 25,2021: Hikma delivers strong performance in 2020
Feb 18,2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30,2020: Amarin files patent infringement lawsuit against Hikma
Nov 05,2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05,2020: Hikma continues strong 2020 performance and updates full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Hikma Pharmaceuticals Plc – Key Facts
Hikma Pharmaceuticals Plc – Key Employees
Hikma Pharmaceuticals Plc – Key Employee Biographies
Hikma Pharmaceuticals Plc – Major Products and Services
Hikma Pharmaceuticals Plc – History
Hikma Pharmaceuticals Plc – Company Statement
Hikma Pharmaceuticals Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Hikma Pharmaceuticals Plc – Business Description
Business Segment: Branded
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Injectables
Overview
Performance
Business Segment: Others
Performance
Geographical Segment: Europe and Rest of the World
Performance
Geographical Segment: MENA
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Hikma Pharmaceuticals Plc – Corporate Strategy
Hikma Pharmaceuticals Plc – SWOT Analysis
SWOT Analysis – Overview
Hikma Pharmaceuticals Plc – Strengths
Hikma Pharmaceuticals Plc – Weaknesses
Hikma Pharmaceuticals Plc – Opportunities
Hikma Pharmaceuticals Plc – Threats
Hikma Pharmaceuticals Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 25, 2021: Hikma delivers strong performance in 2020
Feb 18, 2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30, 2020: Amarin files patent infringement lawsuit against Hikma
Nov 05, 2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05, 2020: Hikma continues strong 2020 performance and updates full year guidance
Oct 20, 2020: Hikma and Arecor expand collaboration
Aug 18, 2020: DoseID launches to expand RFID interoperability and performance in healthcare
Aug 07, 2020: Hikma Pharmaceuticals : Half-year Report
Aug 07, 2020: Hikma delivers strong first half performance and raises full year guidance
Jun 25, 2020: Jochen Gann resigns from the Board of Hikma
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • VOXX International Corporation:企業の戦略・SWOT・財務情報
    VOXX International Corporation - Strategy, SWOT and Corporate Finance Report Summary VOXX International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Aurora Spine Corp (ASG):企業の財務・戦略的SWOT分析
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • Glenmark Pharmaceuticals Limited:企業のM&A・事業提携・投資動向
    Glenmark Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glenmark Pharmaceuticals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Ward Petroleum Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Ward Petroleum Corp (Ward Petroleum) is an independent oil and gas exploration and production company. The company acquires, explores, develops and produces natural gas and petroleum resources. It drills horizontal wells in Garfield County, Oklahoma and Anadarko Basin in Mid-Continent region …
  • Chimerix Inc (CMRX):企業の財務・戦略的SWOT分析
    Summary Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. Chimer …
  • Cellect Biotechnology Ltd (APOP):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …
  • Siddhartha Bank Ltd:電力:M&Aディール及び事業提携情報
    Summary Siddhartha Bank Ltd (Siddhartha Bank) is a financial service provider that offers personal and corporate banking solutions. The company offers savings accounts, deposit accounts, loans, card, nostro accounts, mutual funds and fixed deposits. It provides business loans, home loans, auto loans …
  • T2 Biosystems Inc (TTOO):企業の製品パイプライン分析
    Summary T2 Biosystems Inc (T2 Biosystems) is a provider of clinical diagnostic products in the field of in vitro diagnostics. The company’s T2 magnetic resonance technology allows direct detection in complex samples such as whole blood, serum, plasma, sputum and urine. T2 Biosystems offers T2HemoSta …
  • Evotec AG (EVT):医療機器:M&Aディール及び事業提携情報
    Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory dise …
  • Sandoz Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sandoz Inc (Sandoz), a division of Novartis AG (Novartis), is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biosimilars. The company also provides intermediary products including active pharmaceutical …
  • Dragon Oil Plc:企業の戦略的SWOT分析
    Dragon Oil Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Medicontur Medical Engineering Ltd:製品パイプライン分析
    Summary Medicontur Medical Engineering Ltd (Medicontur) is a developer and manufacturer of intraocular lenses. The company offers hydrophilic and hydrophobic model lenses including monofocal aspheric, toric, and standard monofocal aspheric lenses; preloaded capsular tension rings; PMMA implants; inj …
  • OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Evonik Industries AG (EVK):製薬・医療:M&Aディール及び事業提携情報
    Summary Evonik Industries AG (Evonik), a subsidiary of RAG-Stiftung, is a specialty chemicals company. Its product portfolio includes surfactants, polymers, resins, additives and others. The company’s products find application in various markets, including adhesives and sealants, automotive, agricul …
  • Medical Information Technology, Inc.-医療機器分野:企業M&A・提携分析
    Summary Medical Information Technology, Inc. doing business as Meditech, is a healthcare information technology solutions provider. The company develops, manufactures, licenses and supports computer software products for hospital market. Its software solution supports the complete spectrum of health …
  • Qsc AG (QSC):企業の財務・戦略的SWOT分析
    Summary Qsc AG (Qsc) is a telecommunication company that provides integrated telecommunication and managed services. The company offers services such as cloud and IT outsourcing, Internet of Things services, sap services and consulting, broadband and network services, and colocation services. Its cl …
  • Taiflex Scientific Co., Ltd. (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co., Ltd. (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tokyo Printing Ink Mfg Co Ltd (4635):企業の財務・戦略的SWOT分析
    Tokyo Printing Ink Mfg Co Ltd (4635) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Delek Group Ltd:戦略・SWOT・企業財務分析
    Delek Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Delek Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CooperVision Inc:医療機器:M&Aディール及び事業提携情報
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆